|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?
|
25521938 |
2015 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
|
25986168 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TMEM173 encodes MPYS/STING and is an innate immune sensor for cyclic dinucleotides (CDNs) playing a critical role in infection, inflammation, and cancer.
|
27927967 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
TMEM173 encodes MPYS/STING and is an innate immune sensor for cyclic dinucleotides (CDNs) playing a critical role in infection, inflammation, and cancer.
|
27927967 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
STING protein expression was remarkably decreased in tumor tissues compared to non-tumor tissues, and low STING staining intensity was positively correlated with tumor size, tumor invasion depth, lymph mode metastasis, TNM stage, and reduced patients' survival.
|
28176788 |
2017 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
STING protein expression was remarkably decreased in tumor tissues compared to non-tumor tissues, and low STING staining intensity was positively correlated with tumor size, tumor invasion depth, lymph mode metastasis, TNM stage, and reduced patients' survival.
|
28176788 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
STING protein expression was remarkably decreased in tumor tissues compared to non-tumor tissues, and low STING staining intensity was positively correlated with tumor size, tumor invasion depth, lymph mode metastasis, TNM stage, and reduced patients' survival.
|
28176788 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
MITA modulated autophagy flux promotes cell death in breast cancer cells.
|
28366813 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
MITA modulated autophagy flux promotes cell death in breast cancer cells.
|
28366813 |
2017 |
|
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.
|
28512240 |
2017 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.
|
28512240 |
2017 |
|
Childhood Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.
|
28512240 |
2017 |
|
Malaria
|
0.010 |
Biomarker
|
disease |
BEFREE |
STING is an innate immune cytosolic adaptor for DNA sensors that engage malaria parasite (Plasmodium falciparum) or other pathogen DNA.
|
29215015 |
2017 |
|
Zika Virus Infection
|
0.020 |
Biomarker
|
disease |
BEFREE |
STING-deficient mice, however, did not exhibit increased susceptibility, suggesting that other redundant antiviral pathways control ZIKV infection in vivo.
|
29915078 |
2018 |
|
Vascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
SAVI is an autoinflammatory vasculopathy with increased Interferon (IFN) signature, causing severe skin lesions resulting in ulceration, necrosis, and in some cases, amputation.
|
30560109 |
2018 |
|
Skin lesion
|
0.010 |
Biomarker
|
group |
BEFREE |
SAVI is an autoinflammatory vasculopathy with increased Interferon (IFN) signature, causing severe skin lesions resulting in ulceration, necrosis, and in some cases, amputation.
|
30560109 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SAVI is an autoinflammatory vasculopathy with increased Interferon (IFN) signature, causing severe skin lesions resulting in ulceration, necrosis, and in some cases, amputation.
|
30560109 |
2018 |
|
Tumor Immunity
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
STING has been recognized as an activator of immune responses by TBK1/IRF3 and NF-<i>κ</i>B pathways, and it is suggested to play critical roles in host defense, autoimmune diseases, and tumor immunity.
|
30595664 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
STING-targeted activation is extensively investigated as a new strategy for cancer therapy.
|
30844475 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
STING-targeted activation is extensively investigated as a new strategy for cancer therapy.
|
30844475 |
2019 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Mediator of IRF3 activation (MITA, also known as STING and ERIS) is an essential adaptor protein for cytoplasmic DNA-triggered signaling and involved in innate immune responses, autoimmunity and tumorigenesis.
|
30943264 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
STING agonists are therefore being developed as a novel cancer therapeutic, and a greater understanding of STING pathway regulation is leading to a broadened list of candidate immune regulatory targets.
|
31355488 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
STING agonists are therefore being developed as a novel cancer therapeutic, and a greater understanding of STING pathway regulation is leading to a broadened list of candidate immune regulatory targets.
|
31355488 |
2019 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.
|
31371279 |
2019 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.
|
31371279 |
2019 |